Literature DB >> 16088432

Pulmonary rehabilitation and COPD.

Andrew L Ries1.   

Abstract

Pulmonary rehabilitation has been well established and increasingly recommended in disease management plans for patients with chronic obstructive pulmonary disease. Key elements include a multidisciplinary approach to care, focus on the individual patient, and attention to emotional and social as well as physical aspects of health. Appropriate candidates are symptomatic patients with chronic lung disease who are aware of their disability and motivated to participate actively in their own health care. Pulmonary rehabilitation has also been useful for patients with other types of chronic lung diseases. Program components include a careful patient evaluation, education, instruction in respiratory and chest physiotherapy techniques, exercise training, and psychosocial support. Benefits demonstrated in a growing body of evidence include improvement in symptoms, exercise tolerance, and quality of life and reduction in utilization of health care resources. Pulmonary rehabilitation has also been included as an adjunct to surgical programs such as lung transplantation and lung volume reduction surgery.

Entities:  

Mesh:

Year:  2005        PMID: 16088432     DOI: 10.1055/s-2005-869534

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  2 in total

1.  Which chronic obstructive pulmonary disease patients will be likely to attend consistently a pulmonary rehabilitation program?

Authors:  Salwa E Hassanein; Georgia L Narsavage; Sherrie Dixon Williams; Mary K Anthony; Lisaann S Gittner
Journal:  Perm J       Date:  2007

2.  What determines subjective health status in patients with chronic obstructive pulmonary disease: importance of symptoms in subjective health status of COPD patients.

Authors:  Signe Berit Bentsen; Anne Hildur Henriksen; Tore Wentzel-Larsen; Berit Rokne Hanestad; Astrid Klopstad Wahl
Journal:  Health Qual Life Outcomes       Date:  2008-12-18       Impact factor: 3.186

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.